Answers are grounded in this paper and cite their sources.
Case report of a HER2-expressed ovarian clear cell carcinoma with exceptional response to trastuzumab deruxtecan.
No takes yet. Share an insight, caveat, or question.
Kong et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: